The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.
Joseph A. Sparano
No relevant relationships to disclose
Anne O'Neill
No relevant relationships to disclose
Robert James Gray
Research Funding - Genomic Health
Edith A. Perez
No relevant relationships to disclose
Lawrence N. Shulman
No relevant relationships to disclose
Silvana Martino
No relevant relationships to disclose
Sunil S. Badve
Honoraria - Genomic Health
Frederick L. Baehner
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Barrett H Childs
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Carl N. Yoshizawa
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Steve Rowley
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Nancy E. Davidson
No relevant relationships to disclose
Steven Shak
Employment or Leadership Position - Genomic Health
Stock Ownership - Genomic Health
Lori J. Goldstein
Consultant or Advisory Role - Genomic Health (U)